Alnylam Pharmaceuticals
ALNY
#581
Rank
ยฃ31.29 B
Marketcap
ยฃ236.86
Share price
0.93%
Change (1 day)
6.83%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): ยฃ88.55 Million

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are ยฃ3.21 Billion. In 2024 the company made an earning of -ยฃ0.18 Billion, an increase over its 2023 earnings that were of -ยฃ0.23 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) ยฃ88.55 M-151.27%
2024 -ยฃ0.18 Billion-24.59%
2023 -ยฃ0.23 Billion-67.84%
2022 -ยฃ0.72 Billion36.93%
2021 -ยฃ0.53 Billion-8.04%
2020 -ยฃ0.57 Billion-15.66%
2019 -ยฃ0.68 Billion12.23%
2018 -ยฃ0.6 Billion62.91%
2017 -ยฃ0.37 Billion17.78%
2016 -ยฃ0.32 Billion43.44%
2015 -ยฃ0.22 Billion60.69%
2014 -ยฃ0.14 Billion98.2%
2013 -ยฃ68.16 Million
2011 -ยฃ40.21 Million27.48%
2010 -ยฃ31.54 Million-10.92%
2009 -ยฃ35.41 Million95.77%
2008 -ยฃ18.09 Million
2006 -ยฃ28.97 Million-9.13%
2005 -ยฃ31.89 Million34.74%
2004 -ยฃ23.67 Million36.79%
2003 -ยฃ17.3 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
ยฃ11.99 B 12,447.77%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ6.67 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
ยฃ3.83 B 3,913.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-ยฃ0.19 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-ยฃ34.79 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-ยฃ0.12 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ1.57 B 1,551.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
ยฃ0.10 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA